We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.


The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters


30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787




  • 2016 - 12 - 20

    Menarini Acquires CELLSEARCH Business from American Group Janssen Diagnostics, Pioneer in High-tech Cancer Diagnostics

    Menarini Silicon Biosystems has signed an agreement for the acquisition of the CELLSEARCH CTC business from American company Janssen Diagnostics LLC. At the moment of closing, the ownership of the only system already cleared by the Food and Drug Administration and CE marked for detecting Circulating Tumor Cells (CTC) in cancer patients starting from a liquid biopsy, will pass into the hands of Menarini Silicon Biosystems.
  • 2016 - 12 - 05

    Menarini Group 250 new employees in 10 months

    Florence, 02 December 2016: Menarini pharmaceuticals demonstrates a positive trend in the first 10 months of 2016, with 250 new employees in Italy and 230 around the world. The average age of the new employees is 29. The new hires are 60% male and 40% female and all of them are highly qualified with degrees or technical diplomas, and they join a total of over 16,000 staff in 130 countries around the world. In Italy, Menarini has manufacturing sites, research centres and offices in Florence, Pisa, Milan, L'Aquila, Pomezia, Bologna and Rapolano Terme (Siena).
  • 2016 - 10 - 18

    Paediatric network against ill-treatment of minors

    Tirana, 18th October 2016 – The project for a "Paediatric network against ill- treatment of minors", launched and supported by the pharmaceutical company, Menarini, together with Telefono Azzurro, the Italian Federation of Paediatricians, and the Association of Italian Paediatric Hospitals, has grown beyond Italian borders.
  • 2016 - 01 - 08

    Menarini Group and MSD extends global partnership to the Asia-Pacific region

    Singapore, 09 June 2016 – Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd ("Menarini Asia-Pacific") and MSD have embarked on a multi-year partnership for Menarini Asia-Pacific to assume the sales, marketing and distribution of a number of MSD's pharmaceutical brands in Asia-Pacific since January 2016.
  • 2016 - 05 - 10

    Menarini Launches A Network Of Pediatricians Against Child Abuse, The First In The World. 15 Thousand Sentinel Doctors On Their Way

    There are approximately 70-80 thousand children and adolescents in our country that suffer violence and physical, psychological and sexual abuse every year, but only a few cases come to light. To bring these "suppressed" cases into the open and send a message of tangible assistance to these young, voiceless victims, Menarini has launched the first project worldwide to create an anti-abuse network of 15 thousand "sentinel" pediatricians and general practitioners.
  • 2016 - 03 - 15

    Menarini Announces The Founding Of VaxYnethic, Joint Venture With BiosYnth

    Florence, 16 March 2016 - The Menarini Group announces the founding of VaxYnethic, a joint venture between Menarini NewTech and BiosYnth, pioneer company operating in the field of technologies for the production of conjugated vaccines.
  • 2016 - 02 - 25

    Mitsubishi Tanabe Pharma Corporation Signs Licensing Agreement with A. Menarini Asia-Pacific for Spedra (Avanafil) in 10 Countries in Asia-Pacific

    Singapore, 26 February 2016 – Mitsubishi Tanabe Pharma Corporation (TSE: 4508), and Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd ("Menarini AP") have entered into a licensing agreement to commercialize and promote SPEDRA™ (avanafil). Menarini AP will receive exclusive licensing rights from Mitsubishi Tanabe Pharma Corporation to market Avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam.